Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Pharmasset, Inc. (NASDAQ: VRUS - News) (referred to as "Pharmasset" or the “Company”) to Gilead Sciences, Inc. (“Gilead”) in a cash transaction valued at approximately $11 billion.

Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Pharmasset’s common stock at a price of $137 per share in cash. Following successful completion of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second step merger at the same price as in the tender offer.

Bull & Lifshitz, LLP's investigation is focused on whether the proposed deal provides adequate value to the Company’s shareholders.

If you are a holder of Pharmasset common stock and want to discuss your legal rights, you may e-mail or call Bull & Lifshitz, LLP who will, without obligation or cost to you, attempt to answer your questions.

If you are a shareholder of Pharmasset and would like more information about our investigation, please contact Peter D. Bull, Esq. by telephone at (866) 313-6222 or by sending an e-mail including your contact information to: counsel@nyclasslaw.com. All e-mail correspondence should make reference to Pharmasset.

Bull & Lifshitz, LLP is a New York City-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at www.nyclasslaw.com.

ATTORNEY ADVERTISING . © 2011 Bull & Lifshitz, LLP. The law firm responsible for this advertisement is Bull & Lifshitz, LLP, 18 East 41 st Street, New York, New York 10017, (212) 213-6222. Prior results do not guarantee or predict a similar outcome with respect to any future matter .

Copyright Business Wire 2010

If you liked this article you might like

Idenix Pharma's Hep C Drug Safe But Slow (And Ready For Sale)

Idenix Pharma's Hep C Drug Safe But Slow (And Ready For Sale)

Hep C Deal-A-Palooza: Bristol-Myers Buys Inhibitex for $2.5 Billion

Hep C Deal-A-Palooza: Bristol-Myers Buys Inhibitex for $2.5 Billion

Inhibitex Shares Whipsawed by Cautious Analyst Comment

Inhibitex Shares Whipsawed by Cautious Analyst Comment

5 Big Surprise Stock Winners of 2011

5 Big Surprise Stock Winners of 2011

'Fast Money' Recap: Beaten-Up Financials Eyed

'Fast Money' Recap: Beaten-Up Financials Eyed